Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology

Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology
Urogen Pharma taps cancer expert

Urogen Pharma has named Mark, an internationally recognized expert in urothelial cancer, to help advance its work in urologic oncology.

With decades of clinical and academic leadership, Mark is expected to accelerate research efforts as the company seeks to deliver new progress for patients. Urogen Pharma emphasized Mark's commitment to research as a key driver behind their shared ambition to improve outcomes in the field. Details on specific initiatives and research programs are available on the company’s website.

Urogen Pharma recently attended the SES AUA event in Puerto Rico to engage clinicians and encourage innovation in urologic care. The company continues to focus on collaboration within the clinical community. Its efforts remain centered on developing advances in urologic oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.